Table 1 Baseline patient demographic and clinical characteristics in the idiopathic pulmonary fibrosis study
From: JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers
|  | Placebo n = 5 | CC-930 | All patients N = 28 | ||
|---|---|---|---|---|---|
50 mg QD n = 8 | 100 mg QD n = 8 | 100 mg BID n = 7 | |||
Age, mean (±SD), years | 67.2 (±3.90) | 70.0 (± 6.82) | 62.0 (±7.98) | 69.7 (±7.02) | 67.1 (±7.33) |
Males, n (%) | 3 (60.0) | 8 (100.0) | 5 (62.5) | 4 (57.1) | 20 (71.4) |
Race, n (%) | |||||
 Black | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 1 (3.6) |
 Native  Hawaiian/Pacific Islanders | 0 (0.0) | 1 (12.5) | 0 (0.0) | 0 (0.0) | 1 (3.6) |
 White | 5 (100.0) | 7 (87.5) | 7 (87.5) | 7 (100.0) | 26 (92.9) |
 Weight, mean (±SD), kg | 85.6 (±8.51) | 96.8 (±16.58) | 93.4 (±15.02) | 76.0 (±16.49) | 88.6 (±16.46) |
 Body mass index, mean (±SD), kg/m2 | 28.8 (±2.70) | 29.7 (±4.23) | 31.1 (±2.62) | 27.0 (±2.53) | 29.3 (±3.37) |
 FVC percent of predicted, mean (±SD) | 62.3 (±12.10) | 68.2 (±6.84) | 66.2 (±11.56) | 70.2 (±5.58) | 67.1 (±9.10) |
 DLCO percent of predicted, mean (±SD) | 38.6 (±4.44) | 39.3 (±7.05) | 45.2 (±15.29) | 41.9 (±7.28) | 41.5 (±9.76) |
 SpO2 mean (±SD), % | 96.6 (±1.95) | 95.1 (±1.81) | 96.0 (±1.31) | 94.7 (±1.70) | 95.5 (±1.73) |
 Supplemental oxygen use, n (%) | 1 (20.0) | 0 (0.0) | 3 (37.5) | 2 (28.6) | 6 (21.4) |